Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2018

Comparaison de l’efficacité et de l’innocuité du Tofacitinib et du Baricitinib chez des patients atteints de polyarthrite rhumatoïde active: méta-analyse en réseau bayésiend’essais cliniques contrôlés randomisés

Z Rheumatol. 2018 Sep 6. DOI 10.1007/s00393-018-0531-5

Bae SC and Lee YH

Tofacitinib (TOF) 10mg and baricitinib (BARI) 4mg, in combination with methotrexate (MTX), were the most efficacious treatments in RA patients with an inadequate response to DMARDs or biologics. Both combination treatments presented acceptable safety profiles and were not associated with a significant risk of serious adverse events.This study employed a Bayesian approach to Meta-Analysis; combining the available evidence across a network of Randomised Controlled trials (RCTs).Twelve RCTs contai...

Keywords:

July 2018

Thromboembolie avec des inhibiteurs de Janus Kinase (JAK) dans le cas de la Polyarthrite Rhumatoïde : Quel est le risque réel ?

Drug Safety 2018 Jul;41(7):645–53

Scott IC,

Hider SL,

Scott DL

Current data suggests that JAK inhibitors may increase the risk of thromboembolism and pulmonary thrombosis (PT) in RA.Two JAK inhibitors – baricitinib (BARI) and tofacitinib (TOF) – are considered effective treatments for RA, however, there are concerns about the thromboembolic risks associated with them. In August 2017, the summary of product characteristics for BARI was revised to include a warning of developing DVT and pulmonary embolism (PE), with recommendations that BARI should be used wi...